Inovio Pharmaceuticals. has been granted a patent for nucleic acid molecules encoding a modified consensus mesothelin antigen, along with related vectors, compositions, and vaccines. The patent also includes methods for treating and preventing mesothelin-expressing tumors, highlighting a specific protein sequence with defined amino acid modifications. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of June 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Modified consensus mesothelin antigen for cancer treatment
The granted patent US11986517B2 outlines specific claims related to a protein characterized by its amino acid sequence. Claim 1 describes a protein that includes amino acids 19-607 from SEQ ID NO: 2 or an amino acid sequence that is at least 96% identical to this segment. Notably, this protein must contain specific amino acids at designated positions: alanine at position 303, threonine at position 583, and valine at position 585. Claim 2 expands on this by including the full sequence of SEQ ID NO: 2 and also allows for sequences that maintain at least 96% identity to SEQ ID NO: 2, with the same specified amino acids at the aforementioned positions.
Claim 3 further simplifies the description by asserting the protein comprises the complete amino acid sequence as set forth in SEQ ID NO: 2. Collectively, these claims emphasize the importance of specific amino acid positions and sequence identity in defining the protein's structure and potential functionality, which may have implications for various applications in biotechnology and medicine.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
